ALB and triple-negative breast carcinoma: explored the use of the PD-1 inhibitor tirelizumab in combination with albumin bound paclitaxel, followed by epirubicin/cyclophosphamide as a new adjuvant treatment for triple negative breast cancer in the Phase II TREND trial in 2025, but did not conduct a comparative analysis of the impact of different drug use sequences on adverse reactions.